A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
18 Years and up
Accepting Healthy Volunteers?
Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma
Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.
Adequate hematologic status
Adequate coagulation function
Adequate hepatic function
Adequate renal function
Known primary tumors of central nervous system disease
Known active brain metastases
Known cardiopulmonary disease
- Solid Tumors